帕金森病步态和认知功能的临床特点及相关性研究

《帕金森病步态和认知功能的临床特点及相关性研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、分类号R742.5UDC616.8密级公开帕金森病步态和认知功能的临床特点及相关性研究曾杰培养类别非全日制学位类型学术学位一级学科(专业类)临床医学二级学科(专业)外科学（神外）研究方向帕金森病指导教师王学廉教授（主任医师）培养单位唐都医院神经外科二O一五年十月第四军医大学硕士学位论文目录缩略语表······························································································1中文摘要·······················

2、·······································································3英文摘要······························································································7前言·····························································································12文献回

3、顾·····························································································14正文·····························································································20实验一中晚期帕金森病患者步态和认知功能在双任务实验中的临床特点·······201材料···································

4、························································201.1研究对象················································································201.2实验分组················································································201.3原发性帕金森病患者纳入与排除标准················

5、····························201.4正常人组纳入与排除标准···························································212方法···························································································222.1一般资料·······························································

6、·················222.2认知评估················································································222.3双重任务实验步骤····································································222.4数据处理···········································································

7、·····232.5相关参数及评价指标的说明························································232.6统计学分析·············································································243实验结果·····················································································243.1帕金森病组和正常人

8、群组临床资料···············································243.2帕金森病组在药物“开期”和正常人群组基线步态与平衡资料···········253.3帕金